Stock Analysis on Net
Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Abiomed Inc., liquidity ratios

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Current ratio 7.05 6.11 4.82 6.39 5.84 4.70
Quick ratio 6.13 5.28 4.00 5.50 5.10 4.08
Cash ratio 5.48 4.53 3.36 4.64 4.28 3.30

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).


The organization maintains an exceptionally strong liquidity position throughout the observed six-year period, characterized by high solvency margins and a substantial capacity to cover short-term liabilities. All primary liquidity metrics exhibit a consistent upward trajectory, despite a synchronized contraction during the fiscal year ending March 31, 2020.

Current Ratio
The current ratio increased from 4.70 in 2017 to 7.05 by 2022. Although a decrease to 4.82 was noted in 2020, the ratio recovered strongly in subsequent years, indicating a highly conservative approach to short-term asset management and a significant buffer against liabilities.
Quick Ratio
A similar pattern is observed in the quick ratio, which rose from 4.08 in 2017 to 6.13 in 2022. The decline to 4.00 in 2020 reflects the same trend seen in the current ratio, confirming that the company possesses sufficient liquid assets to meet obligations without relying on the sale of inventory.
Cash Ratio
The cash ratio reflects a steady increase from 3.30 in 2017 to 5.48 in 2022, notwithstanding a temporary decline to 3.36 in 2020. The sustained growth of this ratio demonstrates an aggressive accumulation of cash and cash equivalents relative to current liabilities.

The narrow divergence between the current, quick, and cash ratios suggests that a dominant portion of current assets is held in cash or highly liquid forms rather than inventory. This asset composition minimizes liquidity risk and provides substantial financial flexibility for operational requirements or strategic capital allocations.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Current Ratio

Abiomed Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current assets 976,473 787,965 635,863 677,197 494,271 326,958
Current liabilities 138,457 128,969 131,885 105,998 84,682 69,617
Liquidity Ratio
Current ratio1 7.05 6.11 4.82 6.39 5.84 4.70
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.63 1.85 — — — —
Elevance Health Inc. 1.40 1.47 — — — —
Intuitive Surgical Inc. 4.40 5.08 — — — —
Medtronic PLC 1.86 2.65 — — — —
UnitedHealth Group Inc. 0.77 0.79 — — — —
Current Ratio, Sector
Health Care Equipment & Services 1.13 1.22 — — — —
Current Ratio, Industry
Health Care 1.23 1.31 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= 976,473 ÷ 138,457 = 7.05

2 Click competitor name to see calculations.


The liquidity position of the organization demonstrates substantial strength and growth over the six-year period ending March 31, 2022. Total current assets increased significantly from 326,958 thousand US$ in 2017 to 976,473 thousand US$ in 2022, representing a near tripling of short-term resources. While current liabilities also rose during this period, moving from 69,617 thousand US$ to 138,457 thousand US$, the growth in assets consistently outpaced the growth in obligations.

Current Asset Trend
A consistent upward trajectory in current assets is observed, with the exception of a slight decrease in March 2020. The most significant growth occurred between 2021 and 2022, where assets increased by approximately 188,498 thousand US$.
Current Liability Trend
Current liabilities grew at a steady and moderate pace, nearly doubling over the period. This controlled increase indicates that the expansion of short-term debt and obligations was managed in alignment with the company's overall growth.
Current Ratio Analysis
The current ratio remained exceptionally high throughout the analyzed timeframe, indicating a robust capacity to meet short-term obligations. The ratio peaked at 7.05 in 2022. A notable contraction occurred in March 2020, where the ratio fell to 4.82, though it remained well above the standard threshold for liquidity. Following this dip, the ratio recovered and expanded, reflecting a highly liquid balance sheet by the end of the period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Quick Ratio

Abiomed Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 132,818 232,710 192,341 121,021 42,975 39,040
Short-term marketable securities 625,789 350,985 250,775 370,677 319,274 190,908
Accounts receivable, net 90,608 97,179 84,650 90,809 70,010 54,055
Total quick assets 849,215 680,874 527,766 582,507 432,259 284,003
 
Current liabilities 138,457 128,969 131,885 105,998 84,682 69,617
Liquidity Ratio
Quick ratio1 6.13 5.28 4.00 5.50 5.10 4.08
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 1.06 1.28 — — — —
Elevance Health Inc. 1.27 1.33 — — — —
Intuitive Surgical Inc. 3.56 4.34 — — — —
Medtronic PLC 1.30 1.91 — — — —
UnitedHealth Group Inc. 0.70 0.72 — — — —
Quick Ratio, Sector
Health Care Equipment & Services 0.95 1.04 — — — —
Quick Ratio, Industry
Health Care 0.93 1.00 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 849,215 ÷ 138,457 = 6.13

2 Click competitor name to see calculations.


The liquidity position of the company demonstrates exceptional strength and consistent growth between March 31, 2017, and March 31, 2022. Throughout this period, the organization maintained a high capacity to meet its short-term obligations using its most liquid assets, far exceeding standard industry benchmarks.

Quick Asset Growth
Total quick assets exhibited a significant upward trajectory, increasing from 284,003 thousand US$ in 2017 to 849,215 thousand US$ by 2022. While a moderate contraction occurred in 2020, the overall trend indicates a robust and sustained accumulation of liquid resources over the six-year period.
Current Liabilities Trend
Current liabilities showed a steady increase from 69,617 thousand US$ in 2017 to 138,457 thousand US$ in 2022. This growth is gradual relative to the expansion of quick assets, suggesting that the increase in short-term obligations is well-supported by the company's asset base.
Quick Ratio Performance
The quick ratio remained consistently high, fluctuating between a low of 4.00 in 2020 and a peak of 6.13 in 2022. The ratio increased from 4.08 in 2017 to 5.50 by 2019, followed by a temporary dip in 2020. The subsequent recovery in 2021 and 2022 underscores an increasingly conservative liquidity posture and a superior ability to cover immediate liabilities without relying on inventory liquidation.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Cash Ratio

Abiomed Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 132,818 232,710 192,341 121,021 42,975 39,040
Short-term marketable securities 625,789 350,985 250,775 370,677 319,274 190,908
Total cash assets 758,607 583,695 443,116 491,698 362,249 229,948
 
Current liabilities 138,457 128,969 131,885 105,998 84,682 69,617
Liquidity Ratio
Cash ratio1 5.48 4.53 3.36 4.64 4.28 3.30
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.66 0.78 — — — —
Elevance Health Inc. 0.86 0.95 — — — —
Intuitive Surgical Inc. 2.90 3.66 — — — —
Medtronic PLC 0.85 1.27 — — — —
UnitedHealth Group Inc. 0.36 0.36 — — — —
Cash Ratio, Sector
Health Care Equipment & Services 0.58 0.64 — — — —
Cash Ratio, Industry
Health Care 0.54 0.60 — — — —

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 758,607 ÷ 138,457 = 5.48

2 Click competitor name to see calculations.


An analysis of the liquidity position from 2017 to 2022 reveals a consistent and substantial strengthening of the cash reserve relative to short-term obligations. Total cash assets grew from 229,948 thousand US dollars in 2017 to 758,607 thousand US dollars by March 31, 2022, indicating a significant accumulation of liquid resources over the six-year period.

Cash Asset Accumulation
A sustained upward trajectory in total cash assets is observed, with the balance more than tripling between 2017 and 2022. While a moderate decrease occurred in 2020, the subsequent years showed robust recovery and further expansion, suggesting a strategic prioritization of liquidity.
Liability Management
Current liabilities exhibited a steady increase, rising from 69,617 thousand US dollars in 2017 to 138,457 thousand US dollars in 2022. However, the rate of increase in obligations was significantly outpaced by the growth of cash assets, preventing any erosion of the liquidity cushion.
Cash Ratio Dynamics
The cash ratio remained exceptionally high throughout the period, consistently staying well above the 1.0 threshold. The ratio began at 3.30 in 2017 and reached a peak of 5.48 by 2022. A temporary contraction to 3.36 was noted in 2020, coinciding with a dip in total cash and a peak in current liabilities for that year, before returning to a strong upward trend in 2021 and 2022.

The overall trend indicates an increasingly conservative liquidity profile. The capacity to meet immediate financial obligations without relying on the sale of other current assets or external financing has strengthened significantly, culminating in a highly liquid financial position by the end of the analyzed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?